Laboratoire des Pathog и nes Й mergents (LPE) Fondation M й rieux GABRIEL Network Meeting Presentation Session Les Pensi и res, December 11 th Gl б ucia Paranhos-Baccal а , PhD, HDR Director LPE Facilities � located in Lyon at the Inserm building: 300 m 2 � access to: ‐ P2 and P3 laboratories designed for molecular biology including Affymetrix station, cell culture, viral isolation, cloning and sequencing, … ‐ P4 Laboratory located in the same area; ‐ Technical platforms from the IFR 128 Biosciences: genetic analysis, in vivo screening, imagery and microscope, flux cytometry, proteins production and analysis, bioinformaticians, … http://www.ifr128.prd.fr/ � collaborate with: ‐ Academic scientists ‐ Armed forces Health Service ‐ Pediatricians, physicians, virologists, bacteriologists
LPE and GABRIEL network: How do we work ? External collaborations Hospitals, Academic Research Laboratories and Industries Emerging Pathogens Laboratory Design of molecular tests for Pathogen Discovery multi-pathogens detection to conduct applied research Host- Pathogen Transfer / Training GABRIEL Network Patient (Clinical data associated) Identification of unknown Positive diagnostic Negative diagnostic Pathogens Public Health Surveillance and Alert Prevention and Treatment Epidemiology LPE and Research Activities* � Pulmonary syndrome Pulmonary syndrome- -based based � - Acute Lower Respiratory Infections (ALRI): Pneumonia and Bronchiolitis - Influenza - Tuberculosis drug resistance surveillance � Pathogen Discovery � Pathogen Discovery - Respiratory infections - Encephalitis � Hemorrhagic Fevers, BSL4 Hemorrhagic Fevers, BSL4 � * Please visit LPE Poster numbers: 11, 12, 14, 17, 23, 24, 29 an * Please visit LPE Poster numbers: 11, 12, 14, 17, 23, 24, 29 and 30. d 30.
LPE and Main Research activities � Acute Lower Respiratory Infections (ALRI) - worldwide occurrence; - high spread in poor communities; - the second leading causes of death in low income countries; - represent a major public health problem, especially for children. � Influenza - every year in the United States, on average: - 5% to 20% of the population gets the flu; - more than 200,000 people are hospitalized from flu-related complications; and - about 36,000 people die from flu-related causes. � Tuberculosis drug resistance surveillance - more than 14 million of TB cases worldwide; and more than 8 million new cases every year; - the 500,000 estimated cases of multi-drug resistant TB (MDR-TB) need characterization and surveillance; i t d t f d l i t i LPE the main questions: Respiratory Infections ALRI - Bronchiolitis and Pneumonia Bronchiolitis and Pneumonia Identification Identification: : � Which are the pathogens in the origin of these diseases? - simultaneous molecular identification of more than 20 viruses, atypical bacteria and bacteria. � Which are the severity criteria? - identification of co-infections and host-markers associated. � How to manage the risk of new Influenza Pandemia? - to molecular genotype and detect the mutations conferin resistance to antiviral drugs. *Grants: USB OPTIMUS Foundation (to be announced) and MINEFI (GAP Project).
LPE the main questions: TB MDR/XDR-TB - � MDR-TB molecular detection tools and trends. - Surveys - Epidemiological trends - Improvement on patient management � XDR-TB - Complete genome sequencing to identify new genes confering resistance *Grants: CAMS and M й rieux Alliance (to be announced). LPE the main questions: Pathogen Discovery Pathogen Discovery - � To identify new or mutants emerging pathogens in samples from children and adults suffering of respiratory and other diseases without pathogen association; Strengths: - The BSL3 and BSL4 «Laboratoire P4 - Jean M й rieux» laboratories are a strong asset, - Sophisticated technological platform (high throughput cloning and sequencing). *Grants: A platform in Lyon with academics and companies through a new call for grant of LyonBioP ф le (to be done).
LPE the main questions: Host Markers Host-Pathogen Markers - � Correlation with inflammatory cytokines, CRP and PCT with bacteremic and non-bacteremic or viremic pulmonary syndromes in children and adults specimens. To predict: outcome, severity and mortality. � To Identify and Characterize host markers such as immunomodulators associated with hemorrhagic fever viruses (P4 Laboratory). The LPE Team The LPE Team � Applied Research and Scientific Support; � Technological Transfer and Support; � Training of Laboratory Managers / Technicians.
Recommend
More recommend
